MasTec, Inc. (MTZ) Stock Forecast
Data as of Oct 31, 2026Industrials · Current price $182.95 (+2.72%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 2, 2026 | Maheep Mandloi | Mizuho Securities | $362.00 | +97.9% |
| Mar 2, 2026 | Jamie Cook | Truist Financial | $356.00 | +94.6% |
| Mar 2, 2026 | Steve Fleishman | Wolfe Research | $326.00 | +78.2% |
| Jan 7, 2026 | Sangita Jain | KeyBanc | $264.00 | +44.3% |
| Nov 3, 2025 | Maheep Mandloi | Mizuho Securities | $254.00 | +38.8% |
| Oct 28, 2025 | Maheep Mandloi | Mizuho Securities | $244.00 | +33.4% |
| Oct 9, 2025 | Brian Brophy | Stifel Nicolaus | $237.00 | +29.5% |
| Oct 8, 2025 | Jamie Cook | Truist Financial | $248.00 | +35.6% |
| Sep 4, 2025 | Maheep Mandloi | Mizuho Securities | $215.00 | +17.5% |
| May 5, 2025 | Jamie Cook | Truist Financial | $184.00 | +0.6% |
| May 5, 2025 | Kashy Harrison | Piper Sandler | $175.00 | -4.3% |
| May 5, 2025 | Sangita Jain | KeyBanc | $163.00 | -10.9% |
| Jan 8, 2025 | Joseph Osha | Guggenheim | $195.00 | +6.6% |
| Nov 5, 2024 | Jamie Cook | Truist Financial | $173.00 | -5.4% |
| Nov 4, 2024 | Brent Theilman | D.A. Davidson | $160.00 | -12.5% |
| Oct 22, 2024 | Andrew Kaplowitz | Citigroup | $150.00 | -18.0% |
| Oct 16, 2024 | Alex Rygiel | B.Riley Financial | $151.00 | -17.5% |
| Aug 5, 2024 | Brian Brophy | Stifel Nicolaus | $121.00 | -33.9% |
| May 31, 2024 | Alex Rygiel | B.Riley Financial | $132.00 | -27.8% |
| May 13, 2024 | Sangita Jain | KeyBanc | $120.00 | -34.4% |
Top Analysts Covering MTZ
MTZ vs Sector & Market
| Metric | MTZ | Industrials Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.40 | 2.41 |
| Analyst Count | 33 | 8 | 19 |
| Target Upside | +110.2% | +134.0% | +21.5% |
| P/E Ratio | 32.04 | 31.62 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $16.62B | $17.03B | $17.26B | 13 |
| 2027-12-31 | $17.78B | $18.79B | $19.44B | 13 |
| 2028-12-31 | $20.75B | $20.79B | $20.83B | 9 |
| 2029-03-31 | $4.24B | $4.37B | $4.57B | 5 |
| 2029-06-30 | $4.28B | $4.40B | $4.61B | 5 |
| 2029-09-30 | $4.31B | $4.44B | $4.65B | 5 |
| 2029-12-31 | $5.85B | $6.03B | $6.31B | 5 |
| 2030-03-31 | $4.38B | $4.51B | $4.72B | 5 |
| 2030-06-30 | $4.41B | $4.55B | $4.76B | 5 |
| 2030-09-30 | $4.45B | $4.58B | $4.80B | 5 |
| 2030-12-31 | $6.40B | $6.60B | $6.90B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $8.20 | $8.48 | $9.06 | 12 |
| 2027-12-31 | $9.05 | $10.74 | $13.41 | 12 |
| 2028-12-31 | $11.24 | $12.80 | $14.25 | 4 |
| 2029-03-31 | $2.82 | $2.93 | $3.10 | 4 |
| 2029-06-30 | $4.90 | $5.09 | $5.40 | 4 |
| 2029-09-30 | $5.75 | $5.98 | $6.34 | 4 |
| 2029-12-31 | $5.25 | $5.46 | $5.79 | 4 |
| 2030-03-31 | $3.13 | $3.25 | $3.45 | 4 |
| 2030-06-30 | $5.29 | $5.50 | $5.84 | 4 |
| 2030-09-30 | $6.19 | $6.43 | $6.82 | 4 |
| 2030-12-31 | $5.69 | $5.91 | $6.27 | 4 |
Frequently Asked Questions
What is the analyst consensus for MTZ?
The consensus among 33 analysts covering MasTec, Inc. (MTZ) is Buy with an average price target of $434.25.
What is the highest price target for MTZ?
The highest price target for MTZ is $362.00, set by Maheep Mandloi at Mizuho Securities on 2026-03-02.
What is the lowest price target for MTZ?
The lowest price target for MTZ is $96.00, set by Christian Schwab at Craig-Hallum on 2024-03-04.
How many analysts cover MTZ?
33 analysts have issued ratings for MasTec, Inc. in the past 12 months.
Is MTZ a buy or sell right now?
Based on 33 analyst ratings, MTZ has a consensus rating of Buy (2.00/5) with a +110.2% upside to the consensus target of $434.25.
What are the earnings estimates for MTZ?
Analysts estimate MTZ will report EPS of $8.48 for the period ending 2026-12-31, with revenue estimated at $17.03B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.